Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9146168 | 1.00 | APP (0.61) | APPMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5507858 | 1.00 | APP (0.61) | APPMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9434307 | 0.85 | APP (0.50) | APPMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5100970 | 0.85 | APP (0.50) | APPMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5100967 | 0.85 | APP (0.50) | APPMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3888883 | 0.83 | APP (0.48) | APPMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3888887 | 0.83 | APP (0.48) | APPMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15912585 | 0.81 | APP (0.46) | APPMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1232576 | 0.81 | FFAR1 (0.58) | APPNPC1KDM4EMEN1ALDH1A1 | |
| SCHEMBL28978993 | 0.81 | APP (0.46) | APPMAPTCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109552-A4 | NOVEL DNA-CLEAVING ANTITUMOR AGENTS | RES DEV FOUNDATION (US) | 2007-11-07 | — | — | EP | disclosed |
| US-6908948-B1 | DNA-cleaving antitumor agents | RESEARCH DEVELOPMENT FOUNDATION (US) | 2005-06-21 | — | — | US | disclosed |
| US-6686345-B2 | INCLUDES AN AZA-ENEDIYNE, AZA-ENYNE ALLENE, OR AN AZA-DIALLENE; ARE PREFERABLY NON-HYDROLYZABLE, CATIONIC COMPOUNDS THAT BIND TO NUCLEIC ACIDS. | RESEARCH DEVELOPMENT FOUNDATION | 2004-02-03 | — | — | US | disclosed |
| US-20020132797-A1 | DNA-cleaving antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-19 | — | — | US | disclosed |
| US-6297284-B1 | AZA-ENEDIYNE, AZA-ENYNE ALLENE, OR AN AZA-DIALLENE CATIONIC COMPOUNDS THAT BIND TO NUCLEIC ACIDS. | RESEARCH DEVELOPMENT FOUNDATION | 2001-10-02 | — | — | US | disclosed |
| EP-1109552-A1 | NOVEL DNA-CLEAVING ANTITUMOR AGENTS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000003709-A9 | NOVEL DNA-CLEAVING ANTITUMOR AGENTS | UNIV TEXAS (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000003709-A1 | NOVEL DNA-CLEAVING ANTITUMOR AGENTS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132797-A1 | DNA-cleaving antitumor agents | DNASE1, DNASE1L3, DCLRE1B | APP 4231/4885MAPT 4775/4885CYP1A2 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.